← Leaderboards
Vassiliki Papadimitrakopoulou
Yale University
$1,386,393
Attributed
$2,772,785
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $584.3K · FY2011–15$1M$750K$500K$250K$0
'11
'12
'13
'14
'15
Funding mix
By agency
NIH$2,772,785 · 1
By mechanism
R01$2,772,785 · 1
Top collaborators
- Roy S Herbst5 shared
Most similar at Yale University
Same institution · by research overlap
- Michael Simons$49,269,368
- Katerina Abigail Politi$13,632,706
- Mark A. Lemmon$27,011,161
- Shuangge Ma$12,574,914
- Rajni Mehta$1,413,974
Others in their field
Top investigators on “Clinical Trials”
- Lawrence Corey · Fred Hutchinson Cancer Center$824,102,536
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$622,583,125
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,008,718
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$504,273,077
Research focus
Clinical TrialsAmino Acid SubstitutionAdenocarcinomaBaseBay 54-9085BiologicalAutomobile DrivingAlgorithmsBiopsyBiopsy SpecimenCancer CellCancer Cell GrowthCancer Cell LineCancer EtiologyCancer HistologyCancer ModelCancer PatientCancer PrognosisCancer TherapyCell ProliferationCessation Of LifeClinical DataClinical ResearchDrug Combinations
Grant awards (5)
Personalizing NSCLC Therapy: Exploiting KRAS activated pathways$554,459
R01 · FY2015 · CA
Personalizing NSCLC Therapy: Exploiting KRAS activated pathways$541,243
R01 · FY2014 · CA
Personalizing NSCLC Therapy: Exploiting KRAS activated pathways$527,883
R01 · FY2013 · CA
Personalizing NSCLC Therapy: Exploiting KRAS activated pathways$564,855
R01 · FY2012 · CA
Personalizing NSCLC Therapy: Exploiting KRAS activated pathways$584,345
R01 · FY2011 · CA